LIVE WEBINAR
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
Traditional preclinical models face a 92% clinical failure rate. This webinar introduces Cyagen’s HUGO-GT™ platform to bridge this translational gap. Discover how full-length humanized models empower evaluating therapies like siRNAs for obesity and cardiovascular diseases. Attendees will review real pharmacodynamic data and explore comprehensive end-to-end CRO services.
DATE
July 31, 2026 | 11:00 AM - 1:00 PM (CT)
LOCATION
Online
Introduction
Traditional preclinical animal models present a significant translational gap,
with 92% of therapeutic targets failing when transitioning from discovery stages to human clinical trials.
Standard wild-type and mutant rodent models often fail to accurately predict real human clinical outcomes.
This webinar introduces Cyagen's specialized Humanized Genomic Ortholog (HUGO-GT™) platform as a solution to
bridge this gap. The session details how full-length humanized gene replacement models empower biopharma
partners to evaluate advanced gene-editing therapies—including antisense oligonucleotides (ASOs) and
siRNAs—with high translational efficiency.
Summary
This session addresses the key technical challenges of metabolic and
cardiovascular preclinical drug testing, focusing on target-specific validation data for obesity, type 2
diabetes, and cardiovascular complications. We outline the model generation strategies and in vivo
validation parameters for premium metabolic disease lines, specifically highlighting the B6-hINHBE and
B6-hALK7 obesity models , alongside liver-expressed hypercholesterolemia B6-hPCSK9 tracks. Through real
pharmacodynamic case studies, the webinar presents concrete data demonstrating target mRNA knockdowns and
total body mass adjustments using client-driven siRNA sequences and benchmark therapies like Semaglutide.
Finally, it provides an overview of Cyagen's end-to-end metabolic CRO services, tracking metrics via
advanced instrumentation such as body composition MRI, metabolism cages, and specialized histology assays.
Topics CoveredThe Preclinical Translational Gap: An examination of why standard murine knockouts fail to
accurately predict human clinical outcomes.
Who Should Attend
- Researchers evaluating modern gene therapy modalities (siRNA and ASOs) for chronic metabolic conditions. Researchers that are seeking high-fidelity animal models that preserve full human genetic binding sequences to mitigate clinical development failure rates. Investigators analyzing target-specific lipid-clearing, adiposity-handling, and liver-disease mechanisms (PCSK9, INHBE, ALK7).
Key Takeaways
- Learn about the HUGO-GT™ platform and its engineering advantages over traditional murine models.
- Understand the preclinical translational gap and how whole-genome humanization bridges it.
- Explore the hINHBE and hALK7 pathways and their vital roles in liver-to-fat metabolic signaling.
- Review real preclinical data demonstrating significant target knockdown and weight loss in humanized obesity models.
- Examine cardiovascular de-risking data using the B6-hPCSK9 model challenged with therapeutics like Inclisiran and AZD0780.
- Discover Cyagen’s full portfolio of metabolic disease models and in vivo CRO services
Webinar Presenter
{{value.name}}
{{value.title}}
{{value.company}}
{{value.descript}}
Discover Our Solutions
{{ value.label }}
{{ value.name }}
Explore
Request Information About This Webinar
Whether you're joining live or catching up later, fill out the form to receive materials or updates related to this webinar.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
